ArticleBMC anesthesiology2025
Flurbiprofen@ZIF-8 nanoformulation with potential for analgesia.
Article in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non steroidal anti-inflammatory drugs (NSAIDs) are widely used for analgesic and anti-inflammatory purposes but are often hampered by side effects such as gastrointestinal issues. Flurbiprofen, a potent NSAID, has significant therapeutic potential but may cause adverse effects due to its non-selective cyclooxygenase (COX) inhibition. This study aimed to enhance its efficacy and reduce side effects by developing flurbiprofen-loaded ZIF-8 nanoparticles (FP@ZIF-8). ZIF-8, with its high porosity, pH sensitivity, and biocompatibility, serves as an excellent carrier for targeted drug delivery. FP@ZIF-8 nanoparticles demonstrated successful flurbiprofen encapsulation with a drug loading rate of up to 53% and showed pH-responsive drug release. In vitro studies revealed that FP@ZIF-8 nanoparticles not only promoted the proliferation of human umbilical vein endothelial cells (HUVECs) but also significantly reduced lipopolysaccharide (LPS) -induced reactive oxygen species (ROS) production in RAW264.7 macrophages. In vivo experiments further indicated that FP@ZIF-8 effectively alleviated inflammation-induced pain in mouse models and downregulated key inflammatory cytokines. The biosafety assessment confirmed the excellent biocompatibility and safety of FP@ZIF-8 nanoparticles. These findings suggest that FP@ZIF-8 is a promising drug delivery system for treating inflammatory pain conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.